uniQure (QURE) Raw Materials (2022 - 2024)

uniQure (QURE) posted quarterly Raw Materials of $6.3 million for Q1 2024, down 11.54% quarter-over-quarter from $7.2 million in Q4 2023.

uniQure (QURE) Raw Materials (2022 - 2024) Analysis & Trends

uniQure's Raw Materials history runs 3 years deep, the most recent figure standing at $6.3 million for Q1 2024.

In Q1 2024, Raw Materials changed N/A year-over-year to $6.3 million; the TTM figure through Mar 2024 stood at $6.3 million (changed N/A YoY), while the FY2023 annual figure was $7.2 million, up 99.69% from the prior year.
Raw Materials for Q1 2024 stood at $6.3 million, down from $7.2 million in the prior quarter.
The five-year high for Raw Materials was $7.4 million in Q3 2023, with the low at $1.4 million in Q3 2022.
The 3-year median for Raw Materials is $6.2 million (2023), against an average of $5.3 million.
Peak annual rise in Raw Materials reached 413.2% in 2023, while the deepest fall reached 99.69% in 2023.
uniQure's Raw Materials stood at $3.6 million in 2022, then surged by 99.69% to $7.2 million in 2023, then decreased by 11.54% to $6.3 million in 2024.
Business Quant data shows QURE's Raw Materials at $6.3 million in Q1 2024, $7.2 million in Q4 2023, and $7.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	uniQure	3.37 Bn	3.37 Bn	5.49 Mn

Download Data